PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6848386

Immunoreactive relaxin-like substance in human split ejaculates.

S De Cooman·P Gilliaux·K Thomas
View original source ↗Export metadata ↓

Abstract

Immunoreactive relaxin-like substance concentrations were estimated in whole seminal plasma of normozoospermic patients, in seminal fluid of both fractions of split ejaculates, as well as in the seminal plasma of patients affected by excretory azoospermia of various causes. The relaxin concentration was significantly higher in the first fraction of partitioned ejaculates (P less than 0.001). In cases of azoospermia after vasectomy or after epididymal obstruction, the relaxin levels were similar to the values observed in normozoospermia. Relaxin concentrations, however, were high in cases of congenital agenesis of vasa deferentia and seminal vesicles. Relaxin traced in human male seminal plasma seems thus to have an important extragonadic source, probably localized in the prostate.

Explore related subjects

EjaculationFructoseHumansHydrogen-Ion ConcentrationMaleOligospermiaRadioimmunoassayRelaxinSemenComparative StudyJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S De Cooman, P Gilliaux, K Thomas. 1983. Immunoreactive relaxin-like substance in human split ejaculates.. https://pubmed.ncbi.nlm.nih.gov/6848386/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Efficacy of sildenafil citrate in treatment of erectile dysfunction: impact of associated premature ejaculation and low desire.

OBJECTIVES: To assess the effect of premature ejaculation (PE) and low desire on the efficacy and satisfaction rate of sildenafil in the treatment of erectile dysfunction (ED). METHODS: A total of 586 male patients with ED in association with and without PE or low desire were enrolled in this study. Patients were screened for ED using the International Index for Erectile Function. All patients were also screened for PE and low desire. We compared the responses to the erectile function domain, questions 3 and 4, before and after sildenafil in patients with and without PE or low desire. Overall satisfaction and global efficacy question responses were also assessed in all patients. RESULTS: The mean age +/- SD was 58 +/- 6.4 years. Significant associations were found between the increased duration and severity of ED and the decreased rate of overall satisfaction. Before sildenafil administration, significant differences were found in the erectile function domain, Q3 and Q4 between patients with and without PE or low desire. After sildenafil administration, no significant differences were found in those assessment variables and the presence or absence of PE and low desire. No significant differences were found between the global efficacy question response and the overall satisfaction rate between patients with and without PE or low desire. CONCLUSIONS: The efficacy of sildenafil was negatively affected by an increased duration and severity of ED; however, global efficacy and overall patient satisfaction were not attenuated by PE or low desire.

Ejaculation↗